Search

Your search keyword '"Mogna, Luca"' showing total 45 results
Start Over Author "Mogna, Luca"
45 results on '"Mogna, Luca"'

10. Additional file 1 of A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis

Author

Gioia, Diana Di, Cionci, Nicole Bozzi, Baffoni, Loredana, Amoruso, Angela, Pane, Marco, Mogna, Luca, Gaggìa, Francesca, Lucenti, Maria Ausiliatrice, Bersano, Enrica, Cantello, Roberto, Marchi, Fabiola De, and Mazzini, Letizia

Abstract

Additional file 1: Figure S1. OTUs distribution in the control-diseased dataset for the most representative phyla. a) OTUs distribution for Bacteroidetes, Firmicutes, Actinobacteria and Verrucomicrobia. b) OTUs distribution for Cyanobacteria. Figure S2. OTUs distribution in the control-diseased dataset for the significant families. a) OTUs distribution for Gastranaerophilales; D_4__uncultured bacterium and Clostridiaceae 1. b) OTUs distribution for Clostridiales; Ambiguous_taxa and Clostridiales;D_4__Family XI. Figure S3. Gut bacterial families and genera characteristics at baseline. a) Relative abundance of microbial groups at family level in the control group (C) and diseased group (D); families with a relative abundance less than 0.002 are omitted for the sake of clarity. b) Relative abundance of microbial groups at genus level in the control group (C) and diseased group (D); genera with a relative abundance less than 0.003 are omitted for the sake of clarity. Figure S4. Fecal yeast qPCR counts during the intervention. The graphic was conceived as mean plot reporting also the standard errors. Figure S5. OTUs distribution in ALS patient’s dataset for significant families. a) OTUs distribution for Bacteroidales; other among the ALS patients grouped for different timepoints and not considering the type of treatment. b) OTUs distribution for Baceroidaceae and Rikenellaceae among ALS patients considering the time and the different treatments (Group A and Group B). Table S1. Absolute abundance expressed as means of the number of OTUs for phyla and families that were significantly different between control (C) and diseased subjects (D) at the baseline. Table S2. Absolute abundance expressed as means of the number of OTUs for phyla and families that were significantly different among ALS patients during the study. “Pcorr” corresponds to the adjusted P-value for the comparisons performed. Table S3. DNA concentration and mean counts of the analyzed microbial groups by qPCR in stool samples of ALS patients during the intervention. Table S4. Relative abundance of the main families for each group of subjects during the intervention.

Published
2020
Full Text
View/download PDF

11. Live Biotherapeutic Products, A Road Map for Safety Assessment

Author

Rouanet, Alice, primary, Bolca, Selin, additional, Bru, Audrey, additional, Claes, Ingmar, additional, Cvejic, Helene, additional, Girgis, Haymen, additional, Harper, Ashton, additional, Lavergne, Sidonie N., additional, Mathys, Sophie, additional, Pane, Marco, additional, Pot, Bruno, additional, Shortt, Colette, additional, Alkema, Wynand, additional, Bezulowsky, Constance, additional, Blanquet-Diot, Stephanie, additional, Chassard, Christophe, additional, Claus, Sandrine P., additional, Hadida, Benjamin, additional, Hemmingsen, Charlotte, additional, Jeune, Cyrille, additional, Lindman, Björn, additional, Midzi, Garikai, additional, Mogna, Luca, additional, Movitz, Charlotta, additional, Nasir, Nail, additional, Oberreither, Manfred, additional, Seegers, Jos F. M. L., additional, Sterkman, Luc, additional, Valo, Audrey, additional, Vieville, Frédérique, additional, and Cordaillat-Simmons, Magali, additional

Published
2020
Full Text
View/download PDF

14. Flow Cytometry

Author

Pane, Marco, primary, Allesina, Serena, additional, Amoruso, Angela, additional, Nicola, Stefania, additional, Deidda, Francesca, additional, and Mogna, Luca, additional

Published
2018
Full Text
View/download PDF

16. Potential role of gut microbiota in Amyotrophic Lateral Sclerosis (ALS) pathogenesis (P1.318)

Author

De Marchi, Fabiola, primary, Mazzini, Letizia, additional, Mogna, Luca, additional, Amoruso, Angela, additional, Pane, Marco, additional, Aloisio, Irene, additional, Cionci, Nicole, additional, Gaggìa, Francesca, additional, Lucenti, Ausiliatrice, additional, Bersano, Enrica, additional, Cantello, Roberto, additional, Gioia, Diana DI., additional, and Mogna, Giovanni, additional

Published
2018
Full Text
View/download PDF

17. Searching for the Perfect Homeostasis

Author

Nicola, Stefania, primary, Amoruso, Angela, additional, Deidda, Francesca, additional, Pane, Marco, additional, Allesina, Serena, additional, Mogna, Luca, additional, Del Piano, Mario, additional, and Mogna, Giovanni, additional

Published
2016
Full Text
View/download PDF

27. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to Restore the “Gastric Barrier Effect” in Patients Chronically Treated With PPI

Author

Del Piano, Mario, primary, Anderloni, Andrea, additional, Balzarini, Marco, additional, Ballarè, Marco, additional, Carmagnola, Stefania, additional, Montino, Franco, additional, Orsello, Marco, additional, Pagliarulo, Michela, additional, Tari, Roberto, additional, Soattini, Liliana, additional, Sforza, Filomena, additional, Mogna, Luca, additional, and Mogna, Giovanni, additional

Published
2012
Full Text
View/download PDF

28. Comparison of the Kinetics of Intestinal Colonization by Associating 5 Probiotic Bacteria Assumed Either in a Microencapsulated or in a Traditional, Uncoated Form

Author

Piano, Mario D., primary, Carmagnola, Stefania, additional, Ballarè, Marco, additional, Balzarini, Marco, additional, Montino, Franco, additional, Pagliarulo, Michela, additional, Anderloni, Andrea, additional, Orsello, Marco, additional, Tari, Roberto, additional, Sforza, Filomena, additional, Mogna, Luca, additional, and Mogna, Giovanni, additional

Published
2012
Full Text
View/download PDF

32. Is microencapsulation the future of probiotic preparations? The increased efficacy of gastro-protected probiotics

Author

Del Piano, Mario, primary, Carmagnola, Stefania, additional, Ballarè, Marco, additional, Sartori, Massimo, additional, Orsello, Marco, additional, Balzarini, Marco, additional, Pagliarulo, Michela, additional, Tari, Roberto, additional, Anderloni, Andrea, additional, Strozzi, Gian Paolo, additional, Mogna, Luca, additional, Sforza, Filomena, additional, and Capurso, Lucio, additional

Published
2011
Full Text
View/download PDF

39. Effectiveness of the Two Microorganisms Lactobacillus fermentumLF15 and Lactobacillus plantarumLP01, Formulated in Slow-release Vaginal Tablets, in Women Affected by Bacterial Vaginosis

Author

Vicariotto, Franco, Mogna, Luca, and Del Piano, Mario

Abstract

Bacterial vaginosis (BV) is the most common reason for abnormal vaginal discharge in reproductive-age women and one of its most important causative agents is the gram-variable bacterium Gardnerella vaginalis. BV is not accompanied by significant local inflammation, whereas the “fishy odor” test is always positive. In contrast, aerobic vaginitis (AV) is predominantly associated with Escherichia coli, but Streptococcus agalactiaeand Staphylococcus aureusare also involved. Standard treatment of BV consists of oral or intravaginal antibiotics, although these are unable to spontaneously restore normal flora characterized by a high concentration of lactobacilli. The main limitation is the inability to offer a long-term defensive barrier, thus facilitating relapses and recurrences.

Published
2014
Full Text
View/download PDF

40. Selenium and Zinc Internalized by Lactobacillus buchneriLb26 (DSM 16341) and Bifidobacterium lactisBb1 (DSM 17850)

Author

Mogna, Luca, Nicola, Stefania, Pane, Marco, Lorenzini, Paola, Strozzi, Gianpaolo, and Mogna, Giovanni

Abstract

Minerals, often referred to as micronutrients, are one of the 5 fundamental groups of nutrients needed to sustain life. Micronutrient malnutrition affects >50 of the worldwide population. In particular, zinc (Zn) deficiency is considered an emerging public health problem in India and in other developing countries. Selenium (Se) is another trace mineral essential for humans and animals. Dietary Se exists primarily as selenomethionine and selenocysteine. In addition, Se may be present in its inorganic form (selenite) in some vegetables. To increase the daily intake of these minerals, numerous food supplements containing different inorganic and organic forms of Zn or Se are commercially available. At any rate, it is quite well known that inorganic salts have a very low bioavailability. Organic salts, commonly based on gluconate, orotate, citrate, or other molecules, are characterized by a higher systemic effect. The innovative opportunity of using certain species of probiotics enriched with the 2 minerals could represent an interesting alternative to these preparations. Diet integration with bacteria able to internalize Zn and Se may embody a new application of probiotics.

Published
2012
Full Text
View/download PDF

41. The Innovative Potential of Lactobacillus rhamnosusLR06, Lactobacillus pentosusLPS01, Lactobacillus plantarumLP01, and Lactobacillus delbrueckiiSubsp. delbrueckii LDD01 to Restore the “Gastric Barrier Effect” in Patients Chronically Treated With PPI

Author

Del Piano, Mario, Anderloni, Andrea, Balzarini, Marco, Ballarè, Marco, Carmagnola, Stefania, Montino, Franco, Orsello, Marco, Pagliarulo, Michela, Tari, Roberto, Soattini, Liliana, Sforza, Filomena, Mogna, Luca, and Mogna, Giovanni

Abstract

Gastroesophageal reflux disease is a very widespread condition. In Europe, it is estimated that about 175 million people suffer from this disease and have to chronically take drugs to increase gastric pH. The proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, and esomeprazole are the most widely used drug typology in this regard. However, the inhibition of normal gastric acid secretion has important side effects, the most important being bacterial overgrowth in the stomach and duodenum with a concentration of >105viable cellsmL. As a major consequence of this, many harmful or even pathogenic bacteria contained in some foods could survive the gastric transit and colonize either the stomach itself, the duodenum, or the gut, where they could establish acute and even chronic infections with unavoidable consequences for the host’s health. In other words, the “gastric barrier effect” is strongly reduced or even disrupted. To date, there are no real strategies to deal with this widespread, although still relatively little known, problem. The aim of this study was to confirm the gastric bacterial overgrowth in long-term PPI consumers and to assess the efficacy of some probiotic bacteria, belonging to both genera Lactobacillusand Bifidobacterium, in the reduction of gastric and duodenal bacterial overgrowth, therefore partially restoring the gastric barrier effect against foodborne pathogenic bacteria.

Published
2012
Full Text
View/download PDF

43. Capability of the Two Microorganisms Bifidobacterium breveB632 and Bifidobacterium breveBR03 to Colonize the Intestinal Microbiota of Children

Author

Mogna, Luca, Del Piano, Mario, and Mogna, Giovanni

Abstract

The total number of bacteria present in the gut microbiota of a newborn is consistently lower than the average found in adults, with the extent of this difference being directly related to body weight and age. It could be assumed that a lower number of viable probiotic cells is necessary to achieve significant gut colonization in infants and children. This study assessed the capability of Bifidobacterium breveB632 (DSM 24706) and Bifidobacterium breveBR03 (DSM 16604), 2 strains able to significantly inhibit some gram-negative bacteria in vitro, to integrate into the intestinal microbiota of children.

Published
2014
Full Text
View/download PDF

44. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies

Author

Marco Pane, Nicole Bozzi Cionci, Diana Di Gioia, Letizia Mazzini, Luca Mogna, Angela Amoruso, Roberto Cantello, Francesca Gaggia, Fabiola De Marchi, Irene Aloisio, Ausiliatrice Lucenti, Enrica Bersano, Giovanni Mogna, Mazzini, Letizia, Mogna, Luca, De Marchi, Fabiola, Amoruso, Angela, Pane, Marco, Aloisio, Irene, Cionci, Nicole Bozzi, Gaggìa, Francesca, Lucenti, Ausiliatrice, Bersano, Enrica, Cantello, Roberto, Di Gioia, Diana, and Mogna, Giovanni

Subjects
0301 basic medicine, Adult, Male, Lactobacillus fermentum, Colony Count, Microbial, Gut flora, Microbiology, 03 medical and health sciences, Feces, 0302 clinical medicine, Double-Blind Method, Enterobacteriaceae, Lactobacillus, Yeasts, medicine, microbiota, Escherichia coli, Humans, Bifidobacterium, biology, business.industry, Lactobacillus salivarius, Probiotics, Amyotrophic Lateral Sclerosis, Gastroenterology, biology.organism_classification, medicine.disease, Gastrointestinal Microbiome, Gastrointestinal Tract, 030104 developmental biology, Phenotype, Female, ALS, business, Dysbiosis, Bacteriotherapy, 030217 neurology & neurosurgery, Lactobacillus plantarum, probiotic
Abstract

Background Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in amyotrophic lateral sclerosis (ALS) pathogenesis through a modification of the gut microbiota brain axis. Our study is the first focused on microbiota analysis in ALS patients. Aim Our aim was to study the main human gut microbial groups and the overall microbial diversity in ALS and healthy subjects. Moreover we have examined the influence of a treatment with a specific bacteriotherapy composed of Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) acting on the gastrointestinal barrier. Methods We enrolled 50 ALS patients and 50 healthy controls, matched for sex, age, and origin. Fecal samples were used for total genomic DNA extraction. Enterobacteria, Bifidobacterium spp., Lactobacillus spp., Clostridium sensu stricto, Escherichia coli and yeast were quantified using quantitative polymerase chain reaction approach. Denaturing gradient gel electrophoresis analyses were performed to investigate total eubacteria and yeasts populations. Patients were randomized to double-blind treatment either with microorganisms or placebo for 6 months and monitored for clinical progression and microbiota composition. Results The comparison between ALS subjects and healthy group revealed a variation in the intestinal microbial composition with a higher abundance of E. coli and enterobacteria and a low abundance of total yeast in patients. Polymerase chain reaction denaturing gradient gel electrophoresis analysis showed a cluster distinction between the bacterial profiles of ALS patients and the healthy subjects. The complexity of the profiles in both cases may indicate that a real dysbiosis status is not evident in the ALS patients although differences between healthy and patients exist. The effects of the progression of the disease and of the bacteriotherapy on the bacterial and yeast populations are currently in progress. Conclusions Our preliminary results confirm that there is a difference in the microbiota profile in ALS patients.

Published
2018

45. Three-Month Feeding Integration With Bifidobacterium Strains Prevents Gastrointestinal Symptoms in Healthy Newborns

Author

Irene Aloisio, Flavia Prodam, Enza Giglione, Nicole Bozzi Cionci, Arianna Solito, Simonetta Bellone, Loredana Baffoni, Luca Mogna, Marco Pane, Gianni Bona, Diana Di Gioia, Aloisio, Irene, Prodam, Flavia, Giglione, Enza, Bozzi Cionci, Nicole, Solito, Arianna, Bellone, Simonetta, Baffoni, Loredana, Mogna, Luca, Pane, Marco, Bona, Gianni, and Di Gioia, Diana

Subjects
0301 basic medicine, medicine.medical_specialty, breastfeeding, Endocrinology, Diabetes and Metabolism, ved/biology.organism_classification_rank.species, lcsh:TX341-641, bottle-feeding, Breast milk, Gut flora, Bifidobacterium breve, Gastroenterology, law.invention, 03 medical and health sciences, Probiotic, 0302 clinical medicine, infant colic, law, Lactobacillus, Internal medicine, microbiota, Medicine, functional gastrointestinal disorders, Adverse effect, Feces, Bifidobacterium, Nutrition, Original Research, Nutrition and Dietetics, biology, ved/biology, business.industry, functional gastrointestinal disorder, biology.organism_classification, 030104 developmental biology, business, lcsh:Nutrition. Foods and food supply, 030217 neurology & neurosurgery, probiotic, Food Science
Abstract

Infantile functional gastrointestinal disorders are common in the first months of life. Their pathogenesis remains unknown although evidences suggest multiple independent causes, including gut microbiota modifications. Feeding type, influencing the composition of intestinal microbiota, could play a significant role in the pathogenesis. Previous studies supported probiotic supplementation success against colics, however mainly Lactobacillus spp. were tested. The aim of this study was to evaluate the effectiveness against functional gastrointestinal disorders of a Bifidobacterium breve based probiotic formulation including in the study both breast-fed and bottle-fed subjects. Two hundred and sixty-eight newborns were enrolled within 15 days from birth. One hundred and fifty-five of them effectively entered the study and were randomized in probiotic and placebo group, receiving the formulation for 90 days. The probiotic formulation consists of a 1:1 mixture of 2 strains of B. breve prepared in an oily suspension and administered in a daily dosage of 5 drops containing 108 CFU of each strain. Absolute quantification of selected microbial groups in the faeces was performed using qPCR. Anthropometric data, daily diary minutes of crying, number of regurgitations, vomits and evacuations, and colour and consistency of stools were evaluated before and after treatment. The study confirmed the positive role of breast milk in influencing the counts of target microbial groups, in particular the bifidobacteria community. No adverse events upon probiotic administration were reported, suggesting the safety of the product in this regimen. B. breve counts increased significantly in all administered newborns (p < 0.02). The study demonstrates that a 3 months treatment with B. breve strains in healthy breast-fed newborns helps to prevent functional gastrointestinal disorders, in particular reducing 56% of daily vomit frequency (p < 0.03), decreasing 46.5% of daily evacuation over time (p < 0.03), and improving the stool consistency (type 6 at the Bristol Stool chart instead of type 5) in those at term (p < 0.0001). Moreover, a significant reduction (8.65 vs. 7.98 LogCFU/g of feces, p < 0.03) of B. fragilis in the bottle-fed group receiving the probiotic formulation was observed.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results